<DOC>
	<DOCNO>NCT01374984</DOCNO>
	<brief_summary>This post-marketing study verify clinical benefit VIGIV [ CNJ-016 , Vaccinia Immune Globulin Intravenous ( Human ) , sterile solution ] resolution complication result smallpox vaccination eligible patient treat VIGIV .</brief_summary>
	<brief_title>VA-005 Clinical Outcomes VIGIV Treatment Smallpox Vaccination Complications Vaccinia Infection</brief_title>
	<detailed_description>This open-label Phase 4 study design collect additional data ass safety efficacy VIGIV [ CNJ-016 , Vaccinia Immune Globulin Intravenous ( Human ) , sterile solution ] first 100 consented patient treat VIGIV .</detailed_description>
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Smallpox</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Subjects treat VIGIV deploy US Strategic National Stockpile follow condition : Eczema vaccinatum . Progressive vaccinia . Severe generalize vaccinia . Vaccinia infection individual skin condition burn , impetigo , varicellazoster , poison ivy , individual eczematous skin lesion either activity extensiveness lesion . Aberrant infection induce vaccinia virus include accidental implantation eye ( except case isolated keratitis ) , mouth , area vaccinia infection would constitute special hazard . Informed consent voluntarily sign subject , legal guardian representative participate study . For minor , informed consent form must sign legally acceptable representative appropriate , informed consent/assent must also obtain minor .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>smallpox</keyword>
	<keyword>vaccination</keyword>
	<keyword>complication</keyword>
</DOC>